TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26670916

Group type: EXPERIMENTAL
Intervention: Acupuncture + Kinesiotherapy (G2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Kinesiotherapy (G1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 48
Study: 25109850

Group type: EXPERIMENTAL
Intervention: rhG-CSF
Number of subjects: 178

Group type: COMPARATOR
Intervention: non-rhG-CSF
Number of subjects: 178
Study: 22974536

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Genetically guided strategy (prasugrel for *2 allele carriers, clopidogrel for non-carriers)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Genetically guided strategy for Maoris
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Genetically guided strategy for Pacific Islanders
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Genetically guided strategy under clinical trial event rate scenario
Number of subjects: 1000
Study: 19614894

Group type: EXPERIMENTAL
Intervention: Sunscreen applied at 2 mg/cm²
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sunscreen applied at 1.5 mg/cm²
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sunscreen applied at 1.0 mg/cm²
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sunscreen applied at 0.5 mg/cm²
Number of subjects: 40
Study: 17885859

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 micro g
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 micro g
Number of subjects: 808

Group type: COMPARATOR
Intervention: Fluticasone propionate 88 micro g
Number of subjects: 808
Study: 15233397

Group type: EXPERIMENTAL
Intervention: Microencapsulated fish oil (FO) 1.3 g/d long-chain n-3 FA (n-3 LCPUFA)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Microencapsulated fish oil (FO)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 97
Study: 11239740

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg) with positive expectancy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo with positive expectancy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg) with neutral expectancy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo with neutral expectancy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Comparison of tramadol with positive expectancy vs neutral expectancy
Number of subjects: 83
Study: 10216807

Group type: EXPERIMENTAL
Intervention: Eprosartan (200 mg b.i.d. to 300 mg b.i.d.)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Enalapril (5 mg o.d. to 20 mg o.d.)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 528
Study: 8770795

Group type: EXPERIMENTAL
Intervention: Flex-Foot
Number of subjects: 7

Group type: COMPARATOR
Intervention: SACH, Flex-Foot, Carbon Copy II, Seattle, Quantum
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All prosthetic feet
Number of subjects: 7
Study: 2195425

Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 677981

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31960702

Group type: EXPERIMENTAL
Intervention: Optimism training interventions
Number of subjects: 140
Study: 31503408

Group type: EXPERIMENTAL
Intervention: Intervention group using bi-directional texting platform for home BP measurements.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group using standard practice for home BP measurement reporting.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 0
Study: 27507191

Group type: EXPERIMENTAL
Intervention: Higher anxiety symptoms (upper quartile)
Number of subjects: 2802

Group type: COMPARATOR
Intervention: Lower anxiety symptoms (bottom quartile)
Number of subjects: 2802
Study: 26354212

Group type: EXPERIMENTAL
Intervention: Preventive care awareness campaign
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (pre-campaign)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Affiliation to community-based health insurance (CBHI)
Number of subjects: 600
Study: 24014985

Group type: EXPERIMENTAL
Intervention: 0.5% proparacaine hydrochloride
Number of subjects: 295

Group type: COMPARATOR
Intervention: 0.5% intracameral preservative free xylocaine
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 295
Study: 21074576

Group type: EXPERIMENTAL
Intervention: Deliberating moral dilemmas during the IGT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smelling novel aromas during the IGT
Number of subjects: 0
Study: 20005820

Group type: EXPERIMENTAL
Intervention: 100 hr of intensive remedial instruction
Number of subjects: 0
Study: 17517295

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with anorganic bovine bone and resorbable collagen membrane
Number of subjects: 44

Group type: COMPARATOR
Intervention: No graft or membrane (Control)
Number of subjects: 44
Study: 16091239

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (CART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherence interventions that are multifaceted, flexible, and protracted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherence programs
Number of subjects: 0
Study: 11606959

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Plaque Remover (electric)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Philips‐Jordan HP 510 (electric)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lactona orthodontic toothbrush (manual)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral‐B Advantage Control Grip (manual)
Number of subjects: 33
Study: 9586617

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control saline
Number of subjects: 14
Study: 7925882

Group type: EXPERIMENTAL
Intervention: Topical budesonide (100 micrograms)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Histamine (40 micrograms.ml‐1)
Number of subjects: 9
Study: 2681438

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis for Pneumocystis carinii pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction followed by maintenance therapy
Number of subjects: 0
Study: 378452

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS) 1 gm intravenously at the start of cardiopulmonary bypass and another gram during the procedure
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31959014

Group type: EXPERIMENTAL
Intervention: 1500-mg sodium meals
Number of subjects: 27

Group type: COMPARATOR
Intervention: 3000-mg sodium meals
Number of subjects: 27
Study: 30949747

Group type: EXPERIMENTAL
Intervention: Group A: medical air-pure oxygen-carbogen
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Group B: medical air-carbogen-pure oxygen
Number of subjects: 8
Study: 28505199

Group type: EXPERIMENTAL
Intervention: Incoming emergency call shift
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dispatch shift
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Re‐assessment shift
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control day
Number of subjects: 22
Study: 25466837

Group type: EXPERIMENTAL
Intervention: Mild induced hypothermia (cooling to 32‐34°C for 24 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (uncontrolled temperature)
Number of subjects: 100
Study: 23611332

Group type: EXPERIMENTAL
Intervention: Breast cup group (BC group) - wore breast cups for at least 8 hours during the daytime
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Breast cup group (BC group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Expectant group (EX group) - did not use breast cups
Number of subjects: 90
Study: 16719605

Group type: EXPERIMENTAL
Intervention: Three levels of physical activity intervention
Number of subjects: 874
Study: 15707545

Group type: EXPERIMENTAL
Intervention: Stage-matched counseling from family physician and dietitian
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 143
Study: 10806285

Group type: EXPERIMENTAL
Intervention: Black female patient (actor)
Number of subjects: 164

Group type: COMPARATOR
Intervention: White male patient (actor)
Number of subjects: 164
Study: 8787428

Group type: EXPERIMENTAL
Intervention: Warfarin (oral anticoagulation)
Number of subjects: 45
Study: 1439693

Group type: EXPERIMENTAL
Intervention: Modified EVA‐System with total amplitude reduced to 0.4 mm and a highly flexible file (Cavishape, grain 25 microns)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Axial margin trimmer
Number of subjects: 81
Study: 6383839

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg p.o. q 6 hr X 4) and fluphenazine (2.5 mg p.o. q 6 hr X 4)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Metoclopramide (20 mg q 6 hr X 4)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Amitriptyline plus fluphenazine (AF)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Metoclopramide (M)
Number of subjects: 51
Study: 30740895

Group type: EXPERIMENTAL
Intervention: ASP3662 (11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor)
Number of subjects: 0
Study: 29068578

Group type: EXPERIMENTAL
Intervention: Propofol infusion (5‐6 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol infusion (5‐6 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h) + 6% desflurane inhalation for 15 min before and after cross-clamping
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol infusion (2‐3 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h) + continuous 6% desflurane inhalation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 90
Study: 26636506

Group type: EXPERIMENTAL
Intervention: Minimally invasive manipulative reduction with poking k-wire fixation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (plate group)
Number of subjects: 96
Study: 24471247

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 236

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 236
Study: 21536607

Group type: EXPERIMENTAL
Intervention: Pacifier + 30% sucrose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sterile water without pacifier
Number of subjects: 24
Study: 19653754

Group type: EXPERIMENTAL
Intervention: Masked stop signals
Number of subjects: 0
Study: 16945128

Group type: EXPERIMENTAL
Intervention: Preventive home visits by professional health workers (2 visits per year for 2 years)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (no preventive home visits)
Number of subjects: 196
Study: 12735659

Group type: EXPERIMENTAL
Intervention: salmeterol + fluticasone (50 microg + 250 microg)
Number of subjects: 16
Study: 10709152

Group type: EXPERIMENTAL
Intervention: Zanamivir (3.6 to 16 mg) intranasally two or six times daily for 4 to 5 days
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Zanamivir as an intranasal spray (3.4 mg/nostril), inhaled powder (10 mg), or combination of intranasal and inhaled formulations twice daily for 5 days
Number of subjects: 171
Study: 8930457

Group type: EXPERIMENTAL
Intervention: 500 mg methylprednisolone administered preoperatively
Number of subjects: 111

Group type: COMPARATOR
Intervention: Historical control group receiving 500 mg methylprednisolone as intraoperative bolus
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Preoperative glucocorticosteroids
Number of subjects: 111

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 111
Study: 1411887

Group type: EXPERIMENTAL
Intervention: Cooper's ligament (McVay) repair
Number of subjects: 269

Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Bilateral inguinal hernias
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Unilateral repairs
Number of subjects: 269
Study: 4044467

Group type: EXPERIMENTAL
Intervention: latamoxef 6 g/day for six days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: latamoxef 12 g/day for four days
Number of subjects: 14

Group type: COMPARATOR
Intervention: cefotaxime 12 g/day for seven days
Number of subjects: 14

Group type: COMPARATOR
Intervention: cefoperazone 6 g/day
Number of subjects: 14
Study: 30246667

Group type: EXPERIMENTAL
Intervention: 1 mg/kg oral ketamine, thrice weekly for 21 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 29693314

Group type: EXPERIMENTAL
Intervention: MHC allelic diversity and presence of particular alleles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MHC allele that impairs survival
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic similarity based on MHC sequences
Number of subjects: 0
Study: 27191385

Group type: EXPERIMENTAL
Intervention: Single-hormone closed-loop system with simplified meal bolus strategy
Number of subjects: 12
Study: 25301035

Group type: EXPERIMENTAL
Intervention: Cigarette smokers (past and present)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Increased urinary albumin/creatinine ratio
Number of subjects: 193

Group type: COMPARATOR
Intervention: Overall population (type 2 diabetes patients)
Number of subjects: 193
Study: 21796050

Group type: EXPERIMENTAL
Intervention: Resistance exercise (R)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Combination exercise (Aerobic plus Resistance, AR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Flexibility exercise (F)
Number of subjects: 42
Study: 20157648

Group type: EXPERIMENTAL
Intervention: Pull-out (PL) test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified push-out (MP) test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Push-out (PS) test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hourglass microtensile (HM) test
Number of subjects: 40
Study: 17667567

Group type: EXPERIMENTAL
Intervention: Sugammadex (2.0, 4.0, 8.0, 12.0, or 16.0 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 45
Study: 16207766

Group type: EXPERIMENTAL
Intervention: Statement establishing a personal standard followed by behavior violating that standard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavior violating the standard followed by statement establishing the standard
Number of subjects: 0
Study: 11905866

Group type: COMPARATOR
Intervention: Conventional CO2 pneumoperitoneum (CO2 group; N = 47)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Abdominal wall lifting (AWL group; N = 48)
Number of subjects: 95
Study: 10951430

Group type: EXPERIMENTAL
Intervention: 200 mg anhydrous theophylline immediate-release (IR) capsules
Number of subjects: 18
Study: 7717633

Group type: EXPERIMENTAL
Intervention: Cochlear implant surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computed tomography scans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drill-out procedure
Number of subjects: 0
Study: 2007445

Group type: EXPERIMENTAL
Intervention: Ampicillin during delivery (500 mg i.v./6 h)
Number of subjects: 121

Group type: COMPARATOR
Intervention: No chemoprophylaxis (Control)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Non-carrier women (Control)
Number of subjects: 121
Study: 6261926

Group type: EXPERIMENTAL
Intervention: Oral and smoked delta-9-tetrahydrocannabinol (THC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31520865

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 92
Study: 26847947

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 104
Study: 25886265

Group type: EXPERIMENTAL
Intervention: Positive Memory Training plus Treatment as Usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study: 23370525

Group type: EXPERIMENTAL
Intervention: Salsalate (up to 4 g/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 21266141

Group type: EXPERIMENTAL
Intervention: Big Brain Academy (BBA) - computerized cognitive training program
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Integrated Psychostimulation Program (IPP) - traditional stimulation program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (EANT) - no treatment
Number of subjects: 45
Study: 18635711

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17887993

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 15472657

Group type: EXPERIMENTAL
Intervention: Miconazole chewing gum 20 mg/piece (3.6 mg released), administered 4 times daily
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Brentan gel 2.5 g (50 mg released), administered 4 times daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Miconazole chewing gum
Number of subjects: 140
Study: 11212046

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% induction and maintenance with N2O(66%)-O2-sevoflurane 2% (Group III)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Propofol and fentanyl (Group I)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Propofol and N2O(66%)-O2-sevoflurane 2% (Group II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: N2O(66%)-O2-sevoflurane 2% (Group II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% induction and N2O(66%)-O2-sevoflurane 2% (Group III)
Number of subjects: 45
Study: 9145895

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus rifampin (C + R)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ciprofloxacin alone
Number of subjects: 40
Study: 7955753

Group type: EXPERIMENTAL
Intervention: Gallbladder ejection fraction in patients with abdominal pain
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gallbladder ejection fraction in normal controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gallbladder ejection fraction in patients with elevated sphincter pressures
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gallbladder ejection fraction in patients with normal sphincter pressures
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Abnormal gallbladder ejection fractions in patients with elevated pressures
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Abnormal gallbladder ejection fractions in patients with normal pressures
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sensitivity of gallbladder ejection fraction for detection of elevated pressures
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Specificity of gallbladder ejection fraction for detection of elevated pressures
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Positive predictive value of gallbladder ejection fraction for detection of elevated pressures
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between sphincter pressure and gallbladder ejection fraction
Number of subjects: 30
Study: 3592880

Group type: EXPERIMENTAL
Intervention: Scotch (1 mL of 100-proof per pound of body weight)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vodka (1 mL of 100-proof per pound of body weight)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (orange juice)
Number of subjects: 17
Study: 31907537

Group type: EXPERIMENTAL
Intervention: Plain packaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: Branded packaging
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low IS smokers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High IS smokers
Number of subjects: 50
Study: 29770445

Group type: EXPERIMENTAL
Intervention: Community-based Diabetes Prevention Program (DPP) with financial incentives
Number of subjects: 847
Study: 28302178

Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy plus laser peripheral iridoplasty (LPI + LPIP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 240
Study: 25782894

Group type: EXPERIMENTAL
Intervention: Standard precautions combined with MRSA screening and decolonization
Number of subjects: 4750

Group type: COMPARATOR
Intervention: Standard precautions alone (control)
Number of subjects: 4750
Study: 23719718

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate 400 mg (Groups A, B, D)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate 200 mg (Group C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate (Groups A, B, D)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate (Group C)
Number of subjects: 24
Study: 20946656

Group type: EXPERIMENTAL
Intervention: Silicon-rich artesian aquifer water (SW) (86 mg/L silica)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Purified water of low-silicon content (PW)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Silicon-rich artesian aquifer water (SW)
Number of subjects: 17
Study: 18760000

Group type: EXPERIMENTAL
Intervention: Street- or shelter-based interventions including education, free condom distribution, syringe and needle prescription programs, chest radiography screening for tuberculosis, directly observed therapy for tuberculosis treatment, improvement of personal clothing and bedding hygiene, widespread use of ivermectin for scabies and body louse infestation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic vaccination against hepatitis B virus, hepatitis A virus, influenza, Streptococcus pneumoniae, and diphtheria.
Number of subjects: 0
Study: 16882179

Group type: EXPERIMENTAL
Intervention: Expertise of the doctor
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Waiting time
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Thorough care
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Convenience of consultation
Number of subjects: 119
Study: 14695072

Group type: EXPERIMENTAL
Intervention: Feedback on thyroid function, rheumatoid factor tests and urine cultures
Number of subjects: 96

Group type: COMPARATOR
Intervention: Feedback on lipid and plasma viscosity tests
Number of subjects: 96